Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | COMT | P21964 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | GRK6 | P43250 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5784940 | 0.83 | CLK4 (0.49) | CLK4GRK6PIN1IDO1NOTUM | |
| SCHEMBL12761250 | 0.82 | GP6 (0.37) | MEN1KMT2ALMNAIDO1 | |
| SCHEMBL16719840 | 0.82 | GFER (0.43) | HAO1COMT | |
| SCHEMBL18125264 | 0.80 | COMT (0.35) | COMTPIN1NOTUM | |
| SCHEMBL18424351 | 0.79 | KEAP1 (0.37) | HAO1CA12CA1CA2CA9 | |
| SCHEMBL12536128 | 0.76 | CLK4 (0.45) | CLK4IDO1NOTUMMAOB | |
| SCHEMBL4655029 | 0.75 | GP6 (0.49) | MEN1KMT2ACLK4PTPN1 | |
| SCHEMBL513232 | 0.74 | ALDH1A1 (0.44) | MEN1KMT2AGRK6PIN1IDO1 | |
| SCHEMBL1109610 | 0.74 | ENPP2 (0.32) | IDO1 | |
| SCHEMBL702625 | 0.74 | DCUN1D1 (0.50) | MEN1KMT2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258314-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2025-03-25 | — | — | US | disclosed |
| US-11912659-B2 | EBNA1 inhibitors and methods using same | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220396551-A1 | EBNA1 Inhibitors and Their Method of Use | WISTAR INST (US) | 2022-12-15 | — | — | US | disclosed |
| US-11242317-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3068758-B1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | WISTAR INST (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-105934425-B | EBNA1 inhibitors and methods of use thereof | 威斯塔解剖学和生物学研究所 | 2020-08-07 | — | — | CN | disclosed |
| US-20200181078-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | WISTAR INST (US) | 2020-06-11 | — | — | US | disclosed |
| US-10421718-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180086699-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-20180086699-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-9856214-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856214-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160289185-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-06 | — | — | US | disclosed |
| US-20160289185-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-06 | — | — | US | disclosed |
| EP-3068758-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | The Wistar Institute Of Anatomy And Biology (US) | 2016-09-21 | — | — | EP | disclosed |
| CN-105934425-A | EBNA1 inhibitors and their method of use | 威斯塔解剖学和生物学研究所 | 2016-09-07 | — | — | CN | disclosed |
| WO-2015073864-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258314-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | HAO1 3967/4885CA12 3220/4885CA1 3628/4885 |
| US-11242317-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | HAO1 3967/4885CA12 3220/4885CA1 3628/4885 |
| US-20160289185-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | MCM5, EBNA1BP2, MLLT1 | HAO1 4027/4885CA12 3416/4885CA1 3665/4885 |
| US-20200181078-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | EBNA1BP2, MLLT1, PML | HAO1 3967/4885CA12 3220/4885CA1 3628/4885 |
| US-10421718-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | HAO1 3967/4885CA12 3220/4885CA1 3628/4885 |
| US-11912659-B2 | EBNA1 inhibitors and methods using same | MLLT1, EBNA1BP2, MALT1 | HAO1 3785/4885CA12 3021/4885CA1 3154/4885 |
| US-20180086699-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | EBNA1BP2, MLLT1, PML | HAO1 3967/4885CA12 3220/4885CA1 3628/4885 |
| US-20220396551-A1 | EBNA1 Inhibitors and Their Method of Use | EBNA1BP2, MLLT1, PML | HAO1 3967/4885CA12 3220/4885CA1 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.